A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

774 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-29

Study Completion Date

2021-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2017, China CDC conducted a study titled "A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China". At present, all the infants in the monitoring cohort were over 18 months old and at least one year had elapsed since the last dose of sIPV inoculation.Since there is no any data about the protection duration of two-dose Sabin IPV schedules, China CDC propose to follow up the study cohort to evaluate the proportion of seroprotection of antibody and measure neutralizing antibody titers against poliovirus at over 18 months of age infants after a 2-dose or a 3-dose primary schedule of Sabin IPV in Chinese children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.

NCT03597919

Poliomyelitis

COMPLETED PHASE4

Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China

NCT03546634

Poliomyelitis

COMPLETED PHASE4

Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants

NCT03147560

Polio

COMPLETED PHASE4

Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

NCT05460377

Poliomyelitis

COMPLETED PHASE4

A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

NCT05432141

Poliomyelitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 2017, China CDC conducted a study titled "A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China". This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. At present, all the infants in the monitoring cohort were over 18 months old and at least one year had elapsed since the last dose of sIPV inoculation.

Since there is no any data about the protection duration of two-dose Sabin IPV schedules, China CDC propose to follow up the study cohort when all subjects are at least 18 months old to monitor persistence of antibody. So that, if the antibody levels are not high enough to protect children from the disease, remedial measures can be taken as soon as possible.So China CDC conduct this follow up study ,to

1. Evaluate the proportion of seroprotection of antibody against poliovirus at over 18 months of age infants after a 2-dose or a 3-dose primary schedule of Sabin IPV in Chinese children.
2. Measure neutralizing antibody titers against poliovirus type I, II and III at over 18 months of age infants after 2-dose Sabin IPV schedule, compared with 3-dose Sabin IPV schedule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Poliomyelitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Three-dose schedule for Sabin IPV

Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.

Sabin strain inactivated polio vaccine

Intervention Type BIOLOGICAL

Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.

Two-dose schedule for Sabin IPV

Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.

Sabin strain inactivated polio vaccine

Intervention Type BIOLOGICAL

Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sabin strain inactivated polio vaccine

Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parent or legal guardian agree to participate in the follow study.
* The subject was vaccinated either two doses or three doses Sabin IPV ,collected two blood samples and laboratory test results were available per protocol of pervious study
* The subject is at least 18 months age.

Exclusion Criteria

* Parent or legal guardian does not agree to participate in the follow up study.
* The subject has received any polio vaccine product beyond the protocol of previous study.

Minimum Eligible Age

18 Months

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes